Isolation and characterization of pseudo degradation products of acalabrutinib using ESI-HRMS/MS and NMR: Formation of possible geometrical isomers-Reference-Cited by-同舟云学术

Isolation and characterization of pseudo degradation products of acalabrutinib using ESI-HRMS/MS and NMR: Formation of possible geometrical isomers

Published:2023-02 Issue: Volume:225 Page:115214
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Panda Samikshya,Das Mitalee,Kandula Ravikanth Reddy,Gajjela Raju,Ravuri Naga Durga Harish,Kumar Hemantha,Kalamse Shruti,Mathur Arvind,Roy Amrita,Bagadi Muralidhararao

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference21 articles.

1. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients;Covey;Cancer Res.,2015

2. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia;Byrd;N. Engl. J. Med.,2016

3. ACP-196 is a second-generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity;Harrington;Blood,2015

4. Abstract 1744: ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma;Gardner;Cancer Res.,2014

5. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19;Roschewski;Sci. Immunol.,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isolation and identification of forced degradation products of Febuxostat;SEPARATION SCIENCE PLUS;2024-02-20